25 Monoamine oxidase Inhibitors (MAO-) act astoneurotranemiters Ajantagonists bj

Question

25 Monoamine oxidase Inhibitors (MAO-) act astoneurotranemiters Ajantagonists bjagonists el ipsr d)ESPS 26. Amphetamines increase the of neurotransmiters and decrease the of neurotransmiters e)release binding shows the difference between an effective dose of a drug and the toxic does of a drug, and could djdrug tolerance 27 The be used to indicate a safer drug choice. Ajbinding atinity bjefticacy index ejherapeutic index ejcross-tolerance index The "Just say NO" anti-drug campaign would be using which model of drug abuse? A)disease model biphysical dependence model c)positive reward model djmoral model elew and order model 29 Which is the following is NOT a characteristic of depression? ajsleep disorders bjimpulsiveness c)jnacivity d)suicidal tendencies 30. The primary treatment for Bipolar Disorder is alithium b)MAOI cjtricyclics d)ssRI's e)dopamine blockers 31. Which category of antidepressant drugs block the degrading enzymes? Ajtricycics b) atypical antidepressant 32. In treating depression, Cognitive Behavior Therapy (CBT) focuses on corectng negative thiíing c)SSRis d)MAOlS b)psychosis c)levels of monoamines d)changes in appette

Explanation / Answer

Ans 25 : b) agonist

The monoamine oxidase inhibitors act as indirect agonist to the neurotransmitters such as dopamine , nonadrenaline and serotonin in brain.

They block the action of enzyme monoamine oxidase that removes the neurotransmitters from brain.

Related Questions

Navigate

• Browse (All)
• Browse 2
• Subjects

---

---

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.